Literature DB >> 8267795

Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system.

R G Chirivi1, A Garofalo, I M Padura, A Mantovani, R Giavazzi.   

Abstract

This study examined the ability of the recombinant human interleukin 1 receptor antagonist (IL-1ra) to block interleukin 1 (IL-1)-mediated experimental metastases from the A375M human melanoma. In vivo, IL-1ra administrated at concentrations > or = 200 times IL-1 significantly inhibited the increase in lung colonies induced by IL-1 in nude mice. The response to IL-1 was significantly inhibited when IL-1ra was administered simultaneously with or 1 to 3 h before IL-1. In vitro, the incubation of IL-1-activated endothelial cells with IL-1ra prevented the increase in adhesion of A375M melanoma cells. At the same experimental conditions, IL-1ra inhibited the augmented expression of the intracellular and vascular cell adhesion molecules 1 and E-selectin induced by IL-1 on endothelial cells. Lipopolysaccharide, an IL-1 inducer, increased the number of lung colonies in nude mice. IL-1ra injected with or 1 h after lipopolysaccharide inhibited this augmentation, suggesting a role for host-produced IL-1 in metastasis formation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8267795

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Characterization of novel clonal murine endothelial cell lines with an extended life span.

Authors:  U Cavallaro; V Castelli; A Perilli; R Dossi; R Giavazzi; M S Pepper; M R Soria; R Montesano
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-05       Impact factor: 2.416

2.  IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1.

Authors:  F Vidal-Vanaclocha; G Fantuzzi; L Mendoza; A M Fuentes; M J Anasagasti; J Martín; T Carrascal; P Walsh; L L Reznikov; S H Kim; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

3.  The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC.

Authors:  C W Smith; Z Chen; G Dong; E Loukinova; M Y Pegram; L Nicholas-Figueroa; C Van Waes
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

4.  Nitric oxide reduces tumor cell adhesion to isolated rat postcapillary venules.

Authors:  L Kong; G D Dunn; L K Keefer; R J Korthuis
Journal:  Clin Exp Metastasis       Date:  1996-09       Impact factor: 5.150

Review 5.  Are selectins involved in metastasis?

Authors:  T Krause; G A Turner
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

6.  Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts.

Authors:  Vegard Tjomsland; Anna Spångeus; Johanna Välilä; Per Sandström; Kurt Borch; Henrik Druid; Sture Falkmer; Ursula Falkmer; Davorka Messmer; Marie Larsson
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

7.  Innate immunity, inflammation and tumour progression: double-edged swords.

Authors:  A Mantovani; A Ponzetta; A Inforzato; S Jaillon
Journal:  J Intern Med       Date:  2019-03-14       Impact factor: 8.989

Review 8.  Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity.

Authors:  Alberto Mantovani; Charles A Dinarello; Martina Molgora; Cecilia Garlanda
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

Review 9.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

10.  Cancer cell-derived IL-1alpha induces IL-8 release in endothelial cells.

Authors:  Jung-Hyo Rhim; Sin-Ae Kim; Ji-Eun Lee; Dong-Jo Kim; Hong Keun Chung; Kum-Joo Shin; Junho Chung
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.